Physician profile
Sara E James
NPI 1558895862
$1,618.11
in general payments reported to CMS, 2019-2025
12 companies · $565 in 2025
The $565 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $297 · 2022: $379 · 2023: $192 · 2024: $186 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $942.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $476.62 | 2021-2025 | Wavewriter Alpha Prime 16, Watchman Access System |
| Medtronic, INC. | $304.48 | 2021-2025 | Intellis Adaptivestim, Accurian |
| Mml US, INC. | $255.15 | 2024-2025 | Reactiv8 |
| Stryker Corporation | $185.49 | 2022-2025 | Spinejack, Mild Device Kit |
| Abbott Laboratories | $103.77 | 2021-2025 | Proclaim |
| Nalu Medical, INC. | $101.37 | 2025 | Nalu Neurostimulation System |
| Esperion Therapeutics, INC. | $47.15 | 2024 | Nexletol |
| Vertos Medical, INC. | $39.91 | 2023-2024 | Mild Device Kit |
| Lundbeck LLC | $29.44 | 2023 | Vyepti |
| Abbvie INC. | $29.34 | 2023 | Botox |
| Pacira Pharmaceuticals Incorporated | $24.06 | 2025 | Zilretta, Iovera |
| Merck Sharp & Dohme LLC | $21.33 | 2024 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.